The effects of phenoxodiol on the cell cycle of prostate cancer cell lines

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Mahoney, Simon ^a   Arfuso, Frank ^a,b   Millward, Michael ^c   Dharmarajan, Arun ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cell cycle; Cytotoxicity; Phenoxodiol; Prostate cancer

Indexed keywords

CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; IDRONOXIL; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN D1 GENE; DRUG CYTOTOXICITY; DU145 CELL LINE; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; KI 67 GENE; LNCAP CELL LINE; ONCOGENE C MYC; P21WAF1 GENE; PC3 CELL LINE; PHARMACOGENETICS; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84920833155     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0110-z     Document Type: Article

References (34)

1. Montero A, Fossella F, Hortobagyi G, Valero V: Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005, 6(4):229-239.
2. Canfield SE, Zhu K, Williams SA, McConkey DJ: Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 2006, 5(8):2043-2050.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70.
4. Marieb E, Hoehn K: Human Anatomy and Physiology. 9th edition. Sydney: Pearson; 2012.
5. Cooper S: Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points. FASEB J 2003, 17(3):333-340.
6. Pardee AB: A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 1974, 71(4):1286-1290.
7. Michaud LB, Valero V, Hortobagyi G: Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000, 23(5):401-428.
8. Gan L, Wang J, Xu H, Yang X: Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate 2011, 71 (11):1158-1166.
9. Constantinou AI, Husband A: Phenoxodiol (2H-1-benzopyran-7-0,1,3- (4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 2002, 22(5):2581-2585.
10. Morre DJ, McClain N, Wu LY, Kelly G, Morre DM: Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin. Mol Biotechnol 2009, 42(1):100-109.
11. Mahoney S, Arfuso F, Rogers P, Hisheh S, Brown D, Millward M, Dharmarajan A: Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci 2012, 37(1):73-84.
12. Wasylishen AR, Penn LZ: Myc: the beauty and the beast. Genes Cancer 2010, 1(6):532-541.
13. Ladha MH, Lee KY, Upton TM, Reed MF, Ewen ME: Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol Cell Biol 1998, 18(11):6605-6615.
14. Koda M, Sulkowska M, Kanczuga-Koda L, Tomaszewski J, Kucharczuk W, Lesniewicz T, Cymek S, Sulkowski S: The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer. Oncol Rep 2007, 18(1):113-119.
15. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R: p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007, 6(10):2696-2707.
16. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
17. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, Leung HY, Sansom OJ: Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2011, 2:e124.
18. Bott SR, Arya M, Kirby RS, Williamson M: p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate Cancer Prostatic Dis 2005, 8(4):321-326.
19. Xie W, He Y, Huo D, Huang Y, Wu W: A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1. Med Oncol 2010, 27(4):1340-1345.
20. Senderowicz AM: Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 2004, 16(6):670-678.
21. MacLachlan TK, Sang N, Giordano A: Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995, 5(2):127-156.
22. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, de Vere White RW: Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res 2008, 6(5):808-818.
23. Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S: Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle 2007, 6(23):2953-2961.
24. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4):817-825.
25. Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM: Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 2005, 65(8):3364-3373.
26. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R: Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008, 7(12):1828-1835.
27. Aguero MF, Venero M, Brown DM, Smulson ME, Espinoza LA: Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate 2010, 70(11):1211-1221.
28. Seo YJ, Kim BS, Chun SY, Park YK, Kang KS, Kwon TG: Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. J Korean Med Sci 2011, 26(11):1489-1494.
29. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993, 7(5):812-821.
30. Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H: GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res 2014, 4(5):461-473.
31. Sarkar TR, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, Morrison DK, Wang JM, Sterneck E: Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPdelta expression and contributes to transformation of breast tumor cells. Mol Cell Biol 2012, 32(2):320-332.
32. Schatz JH, Wendel HG: Targeted cancer therapy: what if the driver is just a messenger? Cell Cycle 2011, 10(22):3830-3833.
33. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145(12):5439-5447.
34. Madani SH, Ameli S, Khazaei S, Kanani M, Izadi B: Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Indian J Pathol Microbiol 2011, 54(4):688-691.